 |
diabetes molecular imaging agentsdiabetes molecular imaging agents- Magnetic resonance molecular imaging with nanoparticles |
diabetes molecular imaging agentsMolecular imaging agents are extending the potential of noninvasive medical diagnosis from basic gross anatomic descriptions to complicated phenotypic characterizations based on the recognition of unique cell surface biochemical signatures. Although originally the purview of nuclear medicine, molecular imaging is now a prominent feature of most clinically relevant imaging modalities, in particular magnetic resonance (MR) imaging. MR nanoparticulate agents afford the opportunity not only for targeted diagnostic studies but also for image-monitored site-specific therapeutic delivery, much like the “magic bullet” envisioned by Paul Erhlich 100 years ago. Combining high-resolution MR molecular imaging with drug delivery will facilitate verification and quantification of treatment (ie, rational targeted therapy) and will offer new clinical approaches to many diseases. diabetes molecular imaging agentsMRI of insulitis in autoimmune diabetes diabetes molecular imaging agentsDevelopment of imaging techniques that would allow the mapping of
immune cells in vivo could greatly aid our understanding of a number
of inflammatory and autoimmune diseases. The current study focused
on imaging of autoimmune destruction of the insulin-producing
pancreatic beta-cells by cytotoxic lymphocytes, the cause of
insulin-dependent diabetes mellitus (IDDM; Type 1 diabetes). Using
high-resolution MR microscopy and a conventional clinical MR imaging
system, it was possible to visualize the infiltration of immune
cells in the diabetic mouse pancreas. Mouse lymphocytes were
visualized by magnetically labeling them with recently developed
magnetic nanoparticles (CLIO-Tat). The results from this study could
potentially lead to detection of immune infiltration during diabetes
formation in vivo, which would be one of the earliest parameters of
disease development. Magn Reson Med 47:751-758, 2002. © 2002 Wiley-Liss,
Inc. |
diabetes molecular imaging agents | Cell Point Web MapAddress: 7120 E. Orchard Rd., Suite 350
Centennial, Colorado 80111
|